Large-Cap & Mid-Cap Dashboard

The long-term investor command center. One ticker, the whole case — a Quality / Value / Momentum / Smart-Money read on top of valuation-in-context, ROIC & moat, dividend health, trend, financial health, and who’s buying. Built only from SEC filings and end-of-day prices. Glass-box, no invented numbers.

MAZE

MAZE THERAPEUTICS, INC.Small cap · $1.69B · FY ending 2024-12-31

$30.57-5.71% · 2026-07-10 · EOD

Workspace →Report →

22/100 composite

A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.

Quality0

margins & F-Score

Value32

valuation vs its own range

Momentum57

death · price below 200-day

Smart Money0

selling · 0 funds · 0P/15S insiders

Snapshot

full →

Price

$30.57

Market cap

$1.69B

P/E (TTM)

—

P/S

10.1

EV/EBITDA

—

FCF yield

-6.7%

Revenue

$167.5M

Net margin

-78.3%

Diluted EPS

$-3.05

Dividend yield

none

Trend & momentum

full →

Mixed trendDeath crossBelow 200-day

20-day SMA

$28.05

50-day SMA

$26.57

200-day SMA

$34.47

RSI (14)

neutral

ATR (14)

5.5%

daily range

vs S&P 500

-33.8%

6-mo excess

Trailing performance

1M +27.7%

3M +9.6%

6M -24.3%

YTD -23.1%

1Y +102.7%

Valuation in context

full →

P/E (TTM)

—

P/S

10.1

EV/EBITDA

—

FCF yield

-6.7%

Enterprise value

$1.38B

EBITDA

$-142.9M

Quality & durability

full →

Gross margin

—

Operating margin

-85.3%

Net margin

-78.3%

ROIC

—

Current ratio

17.88

Debt / equity

0.11

ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.

Who's buying

full →

Net selling0P / 15S insiders · 0 funds hold · 0 Congress buys

Recent insiders

Coloma Jason V · Chief Executive OfficerSELL$1.0M

Bernstein Harold · President, R&D & CMOSELL$436,864

Dandekar Atul · CSBOSELL$210,150

Coloma Jason V · Chief Executive OfficerSELL$725,495

Financial health

full →

Chealth · 63/100

Self-funding

Self-funding — generates cash

●Active dilution shelf An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
●One-sided insider selling 15 insider sales and no open-market buys in the recent window.

Latest catalysts

full →

Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.

Full research report →Compare →Small-cap view →

Building MAZE’s long-term case…

Pulling SEC filings

Parsing XBRL fundamentals

Scoring quality, value & momentum

Checking who’s buying

Rendering